Market Overview:
The global immunodiagnostics market size reached US$ 16.2 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 25.2 Billion by 2027, exhibiting a growth rate (CAGR) of 7.8% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemicon different end use sectors. These insights are included in the report as a major market contributor.
Immunodiagnostics refers to an in-vitro diagnostic technology that uses antigen-antibody reaction for the detection of infectious and chronic diseases. It involves the use of radiological, fluorescent or color-forming enzymes and probes for the identification of antibodies that aid in enhancing the targeting range to identify disease progression. Immunodiagnostics also uses various reagents, instruments and software-based solutions for enzyme-linked immunosorbent assay, chemiluminescence, radioimmunoassay and rapid testing. These solutions are widely used for diagnosing diseases, such as cancer and autoimmune, respiratory, endocrine and oncological disorders, along with forensic psychology and environmental and food analysis. As a result, immunodiagnostics finds extensive applications across hospitals, clinical laboratories and research and academic institutes.
Immunodiagnostics Market Trends:
The increasing prevalence of chronic medical ailments and infections among the masses is one of the key factors driving the market growth. Moreover, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the growth of the market. There is also an escalating awareness among the consumers regarding the available treatment alternatives for ailments, such as hepatitis B, diabetes and cancer, which is positively impacting the demand for immunodiagnostics kits, assays and analyzers. Additionally, various technological advancements, such as the development of next-generation immunodiagnostics platforms, are anticipated to drive the market toward growth. These advanced point-of-care testing (POCT) systems offer enhanced diagnostic facilities for sepsis, acute cardiac infractions and other medical disorders with higher mortality rates. Other factors, including the increasing requirement for personalized medicines among the masses, along with extensive improvements in the healthcare infrastructure, especially in the developing economies, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global immunodiagnostics market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, technology, application and end user.
Breakup by Product:
- Reagents
- Instruments
- Software and Services
Breakup by Technology:
- Enzyme-Linked Immunosorbent Assay
- Chemiluminescence Immunoassay
- Fluorescent Immunoassay
- Radioimmunoassay
- Rapid Test
- Others
Breakup by Application:
- Infectious Diseases
- Oncology and Endocrinology
- Hepatitis and Retrovirus
- Bone and Mineral
- Autoimmunity
- Cardiac Biomarker
- Others
Breakup by End User:
- Hospitals
- Clinical Laboratories
- Academic and Research Centers
- Pharmaceutical and Biotechnology Industry
- Others
Breakup by Region:
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arkray Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., F. Hoffmann-La Roche AG, Immunodiagnostic Systems Holdings PLC, Johnson & Johnson, Siemens AG, Sysmex Corporation and Thermo Fisher Scientific Inc.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2021 |
Historical Period |
2016-2021 |
Forecast Period |
2022-2027 |
Units |
US$ Billion |
Segment Coverage |
Product, Technology, Application, End User, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Abbott Laboratories, Arkray Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., F. Hoffmann-La Roche AG, Immunodiagnostic Systems Holdings PLC, Johnson & Johnson, Siemens AG, Sysmex Corporation and Thermo Fisher Scientific Inc. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global immunodiagnostics market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global immunodiagnostics market?
- What are the key regional markets?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the technology?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global immunodiagnostics market and who are the key players?
- What is the degree of competition in the industry?